Abstract:In 2010, the “ShangHai At Risk for Psychosis (SHARP)” study was launched at the Shanghai Mental Health Center (SMHC), the largest outpatient mental health clinic in China. The Chinese SHARP research was led by Dr. Larry Seidman, who was also the PI of the Harvard site of the NAPLS project. He had implemented methods very similar to those used in NAPLS for the identification of clinical high risk (CHR) individuals in Mainland China in studies jointly funded by the United States National Institute of Mental Health and Chinese funding agencies. Dr. Seidman began a collaboration with the SMHC by advising us in carrying out an epidemiological study and then received joint funding for an R21 MH093294 (Fogarty/NIH, “Broadening the Investigation of Psychosis Prodrome to Different Cultural Groups”) designed to implement a variety of clinical, neurocognitive and event related potential (ERP) measures in a preliminary study of CHR. That study, which began in April 2012 and ended in March 2015, aimed to build research capacity at the SMHC. He guide us provided 4 in-person research and clinical skills trainings (2 in SMHC, 2 in Boston), translated a widely used CHR diagnostic instrument (the Structured Interview for Prodromal Symptoms/SIPS), and trained China partners to conduct a preliminary study of 100 CHR individuals. Building upon the R21 project, and the North American Prodrome Longitudinal Studies (NAPLS) model, the same group of researchers led by Dr. Seidman is collaborating on an NIMH R01 101052-01 project (2013 to 2016) to examine biomarkers of CHR with 1 year follow-up. The R21 and R01 collaborations between Harvard Medical School (HMS), MIT, Florida A&M University (FAMU), and SMHC investigators have capitalized on the resources and experiences of the Harvard researchers as members of NAPLS, MIT researchers’ leading role in functional magnetic resonance imaging (fMRI), and FAMU researchers’ expertise in bridging western and Chinese cultures to enhance the existing capacity of Chinese researchers studying the biopsychosocial aspects of CHR. Finally, a stratified cohort of 300 CHR participants was recruited between 2012–2015, and followed up for at least 1 year. With the hope of Dr. Seidman, the SHARP project is ongoing and getting better, larger and stronger. Of the total 417 CHR participants (previous epidemiological survey [CHR, n = 117], R21 [CHR, n = 100], R01 [CHR, n =200]), 349 completed at least a year of follow-up (until August 30, 2017; the longest follow-up case was six and a half years), in which 83 converted to psychosis, and 68 were lost. Preliminary data showed about 20% CHR converted to a psychotic disorder over the course of follow-up, several clinical factors such as 1) functional decline; 2) selected positive symptoms(unusual thoughts and suspiciousness); 3) selected negative symptoms(social anhedonia, expression of emotion, and ideational richness); biological factors such as the P300 auditory ERP; fMRI: Reduced anti-correlation between the bilateral parietal lobule and left dorsolateral prefrontal cortex; Structural MRI: superior temporal gyrus. et al. are account for increasing the risk of conversion to full psychosis. This is the first, well-implemented, longitudinal study of CHR in a low and middle-income country to comprehensively investigate clinical and biological factors in predicting psychosis conversion and illness progression. Dr. Seidman provide a critical step in the implementation of CHR concept in China, just as an obvious need and urgency for prevention and early intervention for Chinese patients with schizophrenia.

Baseline Cortical Thickness Reductions in Clinical High Risk for Psychosis: Brain Regions Associated with Conversion to Psychosis Versus Non-Conversion As Assessed at One-Year Follow-Up in the Shanghai-At-Risk-for-Psychosis (SHARP) Study

Thinner cortex is associated with psychosis onset in individuals at Clinical High Risk for Developing Psychosis: An ENIGMA Working Group mega-analysis

O6.4. AUDITORY AND LANGUAGE AREAS DISTINGUISH CONVERTERS FROM NON–CONVERTERS AT BASELINE IN SHARP CLINICAL HIGH-RISK SUBJECTS FOR PSYCHOSIS STUDY

Association of Structural Magnetic Resonance Imaging Measures with Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis: an ENIGMA Working Group Mega-analysis.

Neuroanatomical Heterogeneity and Homogeneity in Individuals at Clinical High Risk for Psychosis

SU39. Do Baseline Clinical and Neurocognitive Features Predict Conversion in Individuals with Clinical High Risk to Psychosis in Shanghai?

F225. Structural and Tractography Analysis of Clinical High Risk Subjects for Psychosis from the Sharp Study Cohort

Longitudinal Changes in Cortical Surface Area Associated With Transition to Psychosis in Adolescents at Clinical High Risk for the Disease

Cognitive Dysfunction in a Psychotropic Medication-Naïve, Clinical High-Risk Sample from the ShangHai-At-Risk-for-Psychosis (SHARP) Study: Associations with Clinical Outcomes.

M70. Abnormal P300 Novel and P300 Oddball Event Related Potentials in Persons at Clinical High Risk for Psychosis in Shanghai

Cortical and subcortical brain morphometry abnormalities in youth at clinical high-risk for psychosis and individuals with early illness schizophrenia

Functional connectome organization predicts conversion to psychosis in clinical high-risk youth from the SHARP program

A Comparison of Conversion Rates, Clinical Profiles and Predictors of Outcomes in Two Independent Samples of Individuals at Clinical High Risk for Psychosis in China

Sex- and Age-Specific Deviations in Cerebellar Structure and Their Link With Symptom Dimensions and Clinical Outcome in Individuals at Clinical High Risk for Psychosis

Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis

13. the Extents of Extracellular and Brain Tissue Related Abnormalities in Subjects at Clinical High Risk of Psychosis

21.4 BASELINE CLINICAL AND BIOLOGICAL VARIABLES PREDICTING 1 YEAR OUTCOME OF SUBJECTS AT CLINICAL HIGH RISK OF PSYCHOSIS: INSIGHT FROM SHANGHAI AT RISK FOR PSYCHOSIS (SHARP) PROGRAM

Neurocognitive profiles in the prodrome to psychosis in NAPLS-1

Association of Abnormal Cortical Inhibition and Clinical Outcomes in Patients at Clinical High Risk for Psychosis

P300 As an Index of Transition to Psychosis and of Remission: Data from a Clinical High Risk for Psychosis Study and Review of Literature.

Two-Year Follow-Up of A Chinese Sample at Clinical High Risk for Psychosis: Timeline of Symptoms, Help-Seeking and Conversion